Breast cancer currently has a relatively high survival rate, in part due to the prevalence of effective hormone therapies. However, one breast cancer subtype - triple negative breast cancer (TNBC) - has no targeted therapies available. Furthermore, even subtypes of breast cancer with effective therapies available see dramatic decreases in survival rate upon metastasis. IGFR is an upstream activator of the many different cellular growth and migration pathways, and previously studied inhibitors of IGF-1R have shown efficacy in breast cancer. In this study, we tested PQ401, an IGF-1R inhibitor, in MDA-MB-231 cells to determine the compound's effects on cell viability and migration potential. We determined that the EC50 of PQ401 in MDA-MB-231 cells was 1.95 µM, and that treating cells with 2.5 µM PQ401 significantly decreased cellular motility. This study demonstrates that PQ401 not only decreases cell viability, but also migration in a TNBC cell line.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 90 • No. 1